OBJECTIVE： To study the effects of superfine grinding on the powder properties and dissolution of oyster shell， and to provide experimental basis for its comprehensive exploitation. METHODS： Oyster shells were firstly prepared into ordinary powder by grinder. Then the ordinary powder was prepared into micro-powder Ⅰ （crushing 5 min） and Ⅱ （crushing 10 min） by ultrafine pulverizer. The differences of micromeritic properties were investigated before and after superfine grinding from the aspects of particle size distribution， specific surface area and porosity， angle of repose， bulk density， hygroscopicity， etc. Scanning electron microscope （SEM）， Fourier transform infrared spectroscopy （FTIR） and X-ray powder diffraction （XRD） techniques were used to analyze the morphological characteristics and chemical structure of oyster shell before and after superfine grinding. The dissolution were investigated. RESULTS： Compared with ordinary powder， micropowder Ⅰ and micropowder Ⅱ’s were small in particle size and uniformly distributed， but the particles were easy to adhere and aggregate； the specific surface area， porosity and the angle of repose increased， while bulk density decreased； the hygroscopicity increased. FTIR and XRD showed no significant change in chemical structure of oyster shell after superfine grinding. The dissolution rate of micropowder Ⅱ and micropowder Ⅰ was 18.5％ and 10.3％ at 10 min， and the dissolution of ordinary powder was only 6.4％ at 60 min. CONCLUSIONS： Compared with ordinary powder， oyster shell show obvious differences in powder properties after superfine grinding； the dissolution rate of the powders increases， and there is no significant change in chemical structure.

OBJECTIVE：To explore the potential active ingredients and mechanism of Alpinia officinarum in the treatment of gastric ulcer. METHODS ：By network pharmacology method ，the active ingredients and action targets of A. officinarum were screened through TCMSP and TCMID database retrieval [oral bioavailability （OB）≥30％ and drug like （DL）≥0.18] and literature mining. Targets of gastric ulcer were obtained in the TTD ，CTD，OMIM，PubMed，DrugBank and DisGeNet databases. Venny 2.1 software was used to screen common targets for the active ingredients of A. officinarum and gastric ulcer. Then ，the protein-protein interaction（PPI）of the common targets was obtained by STRING database ，and the PPI network was constructed and analysed by using Cytoscape 3.7.1 software. GO function and KEGG pathway enrichment analysis of the common targets were performed by using ClusterProfiler R package. Finally ，Cytoscape 3.7.1 software was used to construct and analyze the network diagram of “active ingredients-targets-pathways ”. RESULTS ：Totally 19 active ingredients of A. officinarum ，209 active ingredients targets and 195 gastric ulcer related targets ，involving 35 common targets ，were screened out. The average node degree of PPI network of common targets was 18，and the average intermediate number was 16.9. There were 11 key targets ，i.e. PTGS2，VEGFA，IL6， IL1B，CCL2，MYC，MMP9，EGFR，HIF1A，ESR1，BCL2L1. The common targets were mainly concentrated in the cell constituents such as the platelet α granule lumen and mitochondria outer membrane ，involved in the biological processes as oxidative stress ，inflammatory response regulation ，and molecular functions as protein phosphatase binding ，growth factor receptor binding. They were also enriched in the signal pathways such as PI3K/Akt，HIF-1. The network of“active ingredients- targets-pathways”showed the active ingredients such as quer- cetin，apigenin，kaempferol and galangin in A. officinarum played an anti-gastric ulcer effect by acting on PTGS2，NOS2， BCL2， IL6， VEGFA， IL1B， MMP9， BCL2L1 and other targets to jointly regulate PI 3K-Akt，HIF-1，TNF，IL-17， NF-κB and other cell proliferation，angiogenesis，and infla- 163.com mmation related pathways. CONCLUSIONS ：A. officinarum shows anti-gastric ulcer effect with the characteristics of multi-ingredient ，multi-target and multi-path.

Ruxolitinib， a small molecule inhibitor， selectively targets Janus kinase （JAK） by competitively binding to adenosine triphosphate on the catalytic site of the JAK1 and JAK2 domain， thereby inhibiting JAK activation and signal transducer and activator of transcription （STAT） phosphorylation and prevents the expressions of the JAK-STAT signaling pathway. Oral ruxolitinib has demonstrated promising efficacy for myelofibrosis and polycythemia vera. The topical Ruxolitinib cream， approved by the US FDA as the first non-segmental vitiligo home treatment drug， is set to be launched in domestic medical pioneer areas in August 2023 and is expected to bring about a breakthrough in the treatment of vitiligo. Clinical cases have also shown that Ruxolitinib cream has significant curative effects on atopic dermatitis， alopecia areata， and other conditions， indicating great application prospects.